(Q33912242)

30 July 2017

title

5-HT(1A) receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex (English)

1 reference

30 July 2017

H Rollema

1

1 reference

30 July 2017

Y Lu

2

1 reference

30 July 2017

A W Schmidt

3

1 reference

30 July 2017

J S Sprouse

4

1 reference

30 July 2017

S H Zorn

5

1 reference

30 July 2017

language of work or name

English

0 references

publication date

1 August 2000

1 reference

30 July 2017

published in

Biological Psychiatry

1 reference

30 July 2017

volume

48

1 reference

30 July 2017

issue

3

1 reference

30 July 2017

page(s)

229-237

1 reference

Prevention by (+/-)-8-hydroxy-2-(di-n-propylamino)tetralin of both catalepsy and the rises in rat striatal dopamine metabolism caused by haloperidol

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900850-7

Ritanserin potentiates the stimulatory effects of raclopride on neuronal activity and dopamine release selectivity in the mesolimbic dopaminergic system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900850-7

(R)-8-OH-DPAT preferentially increases dopamine release in rat medial prefrontal cortex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900850-7

New dimensions in the pharmacologic treatment of schizophrenia and related psychoses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900850-7

Reversal of haloperidol-induced extrapyramidal side effects in cebus monkeys by 8-hydroxy-2-(di-n-propylamino)tetralin and its enantiomers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900850-7

Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900850-7

Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900850-7

An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900850-7

Risperidone: regional effects in vivo on release and metabolism of dopamine and serotonin in the rat brain.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900850-7

3-Benzisothiazolylpiperazine derivatives as potential atypical antipsychotic agents.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900850-7

8-Hydroxy-2-(di-n-propylamino) tetralin, a selective serotonin1A receptor agonist, blocks haloperidol-induced catalepsy by an action on raphe nuclei medianus and dorsalis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900850-7

Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900850-7

Olanzapine increases in vivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900850-7

8-OH-DPAT, a 5-HT1A agonist and ritanserin, a 5-HT2A/C antagonist, reverse haloperidol-induced catalepsy in rats independently of striatal dopamine release

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900850-7

Clozapine has sub-micromolar affinity for 5-HT1A receptors in human brain tissue

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900850-7

Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: an in vivo microdialysis study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900850-7

Clozapine is a partial agonist at cloned, human serotonin 5-HT1A receptors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900850-7

Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900850-7

Systemic administration of amperozide, a new atypical antipsychotic drug, preferentially increases dopamine release in the rat medial prefrontal cortex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900850-7

The atypical antipsychotic drug amperozide enhances rat cortical and striatal dopamine efflux

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900850-7

Ritanserin administration potentiates amphetamine-stimulated dopamine release in the rat prefrontal cortex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900850-7

Clozapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900850-7

Regulation of prefrontal cortical dopamine release by dopamine receptor agonists and antagonists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900850-7

The selective 5-HT2A receptor antagonist, MDL 100,907, increases dopamine efflux in the prefrontal cortex of the rat

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900850-7

Comparison of the novel antipsychotic ziprasidone with clozapine and olanzapine: inhibition of dorsal raphe cell firing and the role of 5-HT1A receptor activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900850-7

BIMG 80, a novel potential antipsychotic drug: evidence for multireceptor actions and preferential release of dopamine in prefrontal cortex.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900850-7

Antipsychotic-like profile of combined treatment with raclopride and 8-OH-DPAT in the rat: enhancement of antipsychotic-like effects without catalepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900850-7

Ipsapirone enhances the dopamine outflow via 5-HT1A receptors in the rat prefrontal cortex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900850-7

Cortical maldevelopment, anti-psychotic drugs, and schizophrenia: a search for common ground

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900850-7

Antipsychotic drugs induce similar effects on the release of dopamine and noradrenaline in the medial prefrontal cortex of the rat brain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900850-7

10.1016/S0006-3223(00)00850-7

7 January 2021

Identifiers

DOI

1 reference

release_ohgj7z7ignfhbpvoa3d3qrcjay

30 July 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ohgj7z7ignfhbpvoa3d3qrcjay

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference